Older melanoma patients respond better to the anti-PD-1 immunotherapy Keytruda (pembrolizumab), according to new data from a multinational study. Researchers believe these differences are due to a reduced immunosuppressive tumor environment in older patients.

Find out further details on the study and its implications in this Immuno-Oncology news article.